# US 2004/0082807 A1 · Novel salt forms of poorly soluble probucol esters and ethers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082807 A1
- Document ID: US20040082807A1
- Status: Published application
- Kind: A1
- Application number: 10/619,268
- Filed: 2003-07-14
- Published: 2004-04-29
- Earliest claimed: 2002-07-12
- Assignees: AtheroGenics, Inc.
- Inventors: Charles Q. Meng
- Web page: https://patentgrep.com/patent/US20040082807A1

## CPC

- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/225: Polycarboxylic acids
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 323/20: with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Organic amine salts of compounds of the formula: 1 and their pharmaceutically acceptable salts, and uses in medical therapy are provided.

## Claims

### Claim 1

A meglumine salt represented by the formula:
25
wherein:
R1 and R2 are independently hydrogen or alkyl or taken together to form a carbonyl; and
Y is (CH2)0-5; and when R1 and R2 taken together form a carbonyl, Y is (CH2)1-5.

### Claim 2

A meglumine salt represented by the formula:
26
wherein:
Y is (CH2)1-5.

### Claim 3 (depends on 2)

The salt of claim 2, wherein Y is (CH2).

### Claim 4 (depends on 2)

The salt of claim 2 wherein Y is (CH2)2.

### Claim 5 (depends on 2)

The salt of claim 2 wherein Y is (CH2)3.

### Claim 6 (depends on 2)

The salt of claim 2 wherein Y is (CH2)4.

### Claim 7 (depends on 2)

The salt of claim 2 wherein Y is (CH2)5.

### Claim 8

A meglumine salt represented by the formula:
27
wherein:
Y is (CH2)0-5.

### Claim 9 (depends on 8)

The salt of claim 8, wherein Y is (CH2)0.

### Claim 10 (depends on 8)

The salt of claim 8 wherein Y is (CH2).

### Claim 11 (depends on 8)

The salt of claim 8 wherein Y is (CH2)2.

### Claim 12 (depends on 8)

The salt of claim 8 wherein Y is (CH2)3.

### Claim 13 (depends on 8)

The salt of claim 8 wherein Y is (CH2)4.

### Claim 14 (depends on 8)

The salt of claim 8 wherein Y is (CH2)5.

### Claim 15

A meglumine salt selected from the group consisting of:
butanedioic acid, mono [4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]ester, meglumine salt; acetic acid, [4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methyl-ethyl] thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-, meglumine salt; and butanoic acid, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)4-hydroxyphenyl]thio]-1-methyl-ethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-, meglumine salt.

### Claim 16

A pharmaceutical composition comprising a meglumine salt represented by the formula:
28
wherein:
R1 and R2 are independently hydrogen or alkyl or taken together to form a carbonyl; and
Y is (CH2)0-5; when R1 and R2 taken together form a carbonyl, Y is (CH2)1-5;
together with a pharmaceutically acceptable carrier.

### Claim 17

A pharmaceutical composition comprising a meglumine salt represented by the formula:
29
wherein:
Y is (CH2)1-5;
together with a pharmaceutically acceptable carrier.

### Claim 18 (depends on 17)

The pharmaceutical composition of claim 17, wherein Y is (CH2).

### Claim 19 (depends on 17)

The pharmaceutical composition of claim 17 wherein Y is (CH2)2.

### Claim 20 (depends on 17)

The pharmaceutical composition of claim 17 wherein Y is (CH2)3.

### Claim 21 (depends on 17)

The pharmaceutical composition of claim 17 wherein Y is (CH2)4.

### Claim 22 (depends on 17)

The pharmaceutical composition of claim 17 wherein Y is (CH2)5.

### Claim 23

A pharmaceutical composition comprising a meglumine salt represented by the formula:
30
wherein:
Y is (CH2)0-5; when R1 and R2 taken together form a carbonyl, Y is (CH2)1-5;
together with a pharmaceutically acceptable carrier.

### Claim 24 (depends on 23)

The pharmaceutical composition of claim 23, wherein Y is (CH2)0.

### Claim 25 (depends on 23)

The pharmaceutical composition of claim 23 wherein Y is (CH2).

### Claim 26 (depends on 23)

The pharmaceutical composition of claim 23 wherein Y is (CH2)1.

### Claim 27 (depends on 23)

The pharmaceutical composition of claim 23 wherein Y is (CH2)3.

### Claim 28 (depends on 23)

The pharmaceutical composition of claim 23 wherein Y is (CH2)4.

### Claim 29 (depends on 23)

The pharmaceutical composition of claim 23 wherein Y is (CH2)5.

### Claim 30

A pharmaceutical composition comprising a compound of the formula:
31
wherein:
R1 and R2 are independently hydrogen or alkyl or taken together to form a carbonyl; and
Y is (CH2)0-5; when R1 and R2 taken together form a carbonyl, Y is (CH2)1-5;
together with meglumine and a pharmaceutically acceptable carrier.

### Claim 31

A pharmaceutical composition comprising a compound of the formula:
32
wherein:
Y is (CH2)1-5;
together with meglumine and a pharmaceutically acceptable carrier.

### Claim 32 (depends on 31)

The pharmaceutical composition of claim 31, wherein Y is (CH2).

### Claim 33 (depends on 31)

The pharmaceutical composition of claim 31 wherein Y is (CH2)2.

### Claim 34 (depends on 31)

The pharmaceutical composition of claim 31 wherein Y is (CH2)3.

### Claim 35 (depends on 31)

The pharmaceutical composition of claim 31 wherein Y is (CH2)4.

### Claim 36 (depends on 31)

The pharmaceutical composition of claim 31 wherein Y is (CH2)5.

### Claim 37

A pharmaceutical composition comprising a compound of the formula:
33
wherein:
Y is (CH2)0-5; when R1 and R2 taken together form a carbonyl, Y is (CH2)1-5;
together with meglumine and a pharmaceutically acceptable carrier.

### Claim 38 (depends on 37)

The pharmaceutical composition of claim 37, wherein Y is (CH2)0.

### Claim 39 (depends on 37)

The pharmaceutical composition of claim 37, wherein Y is (CH2).

### Claim 40 (depends on 37)

The pharmaceutical composition of claim 37 wherein Y is (CH2)2.

### Claim 41 (depends on 37)

The pharmaceutical composition of claim 37 wherein Y is (CH2)3.

### Claim 42 (depends on 37)

The pharmaceutical composition of claim 37 wherein Y is (CH2)4.

### Claim 43 (depends on 37)

The pharmaceutical composition of claim 37 wherein Y is (CH2)5.

### Claim 44 (depends on 1)

A method for the treatment of an inflammatory disorder, comprising administering to a host in need thereof an effective treatment amount of the salt of claim 1.

### Claim 45 (depends on 44)

The method of claim 44, wherein the inflammatory disorder is arthritis.

### Claim 46 (depends on 44)

The method of claim 44, wherein the inflammatory disorder is rheumatoid arthritis.

### Claim 47 (depends on 44)

The method of claim 44, wherein the inflammatory disorder is osteoarthritis.

### Claim 48 (depends on 44)

The method of claim 44, wherein the inflammatory disorder is asthma.

### Claim 49 (depends on 44)

The method of claim 44, wherein the inflammatory disorder is multiple sclerosis.

### Claim 50 (depends on 44)

The method of claim 44, wherein the inflammatory disorder is psoriasis.

### Claim 51 (depends on 1)

A method for the treatment of a cardiovascular disorder, comprising administering to a host in need thereof an effective treatment amount of the salt of claim 1.

### Claim 52 (depends on 51)

The method of claim 51, wherein the cardiovascular disorder is atherosclerosis.

### Claim 53 (depends on 51)

The method of claim 51, wherein the cardiovascular disorder is postangioplasty restenosis.

### Claim 54 (depends on 51)

The method of claim 51, wherein the cardiovascular disorder is coronary artery disease.

### Claim 55 (depends on 51)

The method of claim 51, wherein the cardiovascular disorder is small artery disease.

### Claim 56 (depends on 51)

The method of claim 51, wherein the cardiovascular disorder is angina.

### Claim 57 (depends on 1)

A method for treatment of a disorder mediated by VCAM-1, comprising administering to a host in need thereof an effective treatment amount of the salt of claim 1.

### Claim 58 (depends on 1)

A method of treating an immune response, comprising administering to a host in need thereof an effective treatment amount of the salt of claim 1.

### Claim 59 (depends on 58)

The method of claim 58, wherein the immune response is solid organ transplant rejection.

### Claim 60

An organic amine salt represented by the formula:
34
wherein:
R1 and R2 are independently hydrogen or alkyl or taken together to form a carbonyl; and
Y is (CH2)0-5; when R1 and R2 taken together form a carbonyl, Y is (CH2)1-5.

### Claim 61

An organic amine salt represented by the formula:
35
wherein:
Y is (CH2)1-5.

### Claim 62

An organic amine salt represented by the formula:
36
wherein:
Y is (CH2)0-5.

### Claim 63 (depends on 60, 61, 62)

A method for the treatment of an inflammatory disorder, comprising administering to a host in need thereof an effective treatment amount of the salt of any one of claims 60-62.

### Claim 64 (depends on 60, 61, 62)

A method for the treatment of a cardiovascular disorder, comprising administering to a host in need thereof an effective treatment amount of the salt of any one of claims 60-62.

### Claim 65 (depends on 60, 61, 62)

A method for treatment of a disorder mediated by VCAM-1, comprising administering to a host in need thereof an effective treatment amount of the salt of any one of claims 60-62.

### Claim 66 (depends on 60, 61, 62)

A method of treating an immune response, comprising administering to a host in need thereof an effective treatment amount of the salt of any one of claims 60-62.

### Claim 67

A pharmaceutical composition represented by the formula:
37
wherein:
R1 and R2 are independently hydrogen or alkyl or taken together to form a carbonyl; and
Y is (CH2)0-5; when R1 and R2 taken together form a carbonyl, Y is (CH2)1-5;
together with a pharmaceutically acceptable carrier.

### Claim 68

A pharmaceutical composition represented by the formula:
38
wherein:
Y is (CH2)1-5;
together with a pharmaceutically acceptable carrier.

### Claim 69

A pharmaceutical composition represented by the formula:
39
wherein:
Y is (CH2)0-5; when R1 and R2 taken together form a carbonyl, Y is (CH2)1-5;
together with a pharmaceutically acceptable carrier.

### Claim 70

A compound of the formula:
40
wherein:
R1 and R2 are independently hydrogen or alkyl or taken together to form a carbonyl; and
Y is (CH2)0-5; when R1 and R2 taken together form a carbonyl, Y is (CH2)1-5;
together with an organic amine, optionally in a pharmaceutically acceptable carrier.

### Claim 71

A compound of the formula:
41
wherein:
Y is (CH2)1-5;
together with an organic amine, optionally in a pharmaceutically acceptable carrier.

### Claim 72

A compound of the formula:
42
wherein:
Y is (CH2)0-5;
together with an organic amine, optionally in a pharmaceutically acceptable carrier.

### Claim 73 (depends on 70, 71, 72)

The compound of any one of claims 70-72, wherein the organic amine is a primary amine.

### Claim 74 (depends on 70, 71, 72)

The compound of any one of claims 70-72, wherein the organic amine is a secondary amine.

### Claim 75 (depends on 70, 71, 72)

The compound of any one of claims 70-72, wherein the organic amine is a tertiary amine.

### Claim 76 (depends on 70, 71, 72)

The compound of any one of claims 70-72, wherein the organic amine is substituted with one or more hydroxy or hydroxyalkyl groups.

### Claim 77 (depends on 76)

The compound of claim 76, wherein the hydroxy or hydroxyalkyl substituted organic amine is cyclic.

### Claim 78 (depends on 76)

The compound of claim 76, wherein the hydroxy or hydroxyalkyl substituted organic amine is acyclic.

### Claim 79 (depends on 76)

The compound of claim 76, wherein the hydroxy or hydroxyalkyl substituted organic amine is an amino sugar.

### Claim 80 (depends on 79)

The compound of claim 79, wherein the amino sugar is derived from a substituted and unsubstituted monosaccharide, disaccharide, oligosaccharide, or polysaccharide.

### Claim 81 (depends on 79)

The compound of claim 79, wherein the amino sugar is derived from a substituted and unsubstituted monosaccharide.

### Claim 82 (depends on 79)

The compound of claim 79, wherein the amino sugar is derived from an aldose or ketose.

### Claim 83 (depends on 79)

The compound of claim 79, wherein the amino sugar is derived from a pyranose and furanose.

### Claim 84 (depends on 79)

The compound of claim 79, wherein the amino sugar is derived from the group consisting of threose, ribulose, ketose, gentiobiose, aldose, aldotetrose, aldopentose, aldohexose, ketohexose, ketotetrose, ketopentose, erythrose, threose, ribose, deoxyribose, arabinose, xylose, lyxose, allose, altrose, glucose, mannose, gulose, idose, glactose, talose, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, dextrose, maltose, lactose, sucrose, cellulose, aldose, amylose, palatinose, trehalose, turanose, cellobiose, amylopectin, glucosamine, mannosamine, fucose, phamnose, glucuronate, gluconate, glucono-lactone, muramic acid, abequose, rhamnose, gluconic acid, glucuronic acid, and galactosamine.

### Claim 85 (depends on 79)

The compound of claim 79, wherein the amino sugar is derived from a (L or D)-ribose.

### Claim 86 (depends on 79)

The compound of claim 79, wherein the amino sugar is derived from a substituted and unsubstituted alditol.

### Claim 87 (depends on 86)

The compound of claim 86, wherein the substituted and unsubstituted alditol is derived from the reduction of a monosaccharide.

### Claim 88 (depends on 87)

The compound of claim 87, wherein the monosaccharide is a pyranose or furanose.

### Claim 89 (depends on 86)

The compound of claim 86, wherein the substituted and unsubstituted alditol is represented by the formula
43
wherein:
X and Z are independently hydrogen; unsubstituted C1-4 alkyl or substituted by one or more substituents selected from hydroxy, C1-4 alkyl, or halogen; or taken together to form a carbocyclic ring;
R is hydrogen, C1-8alkyl, or —(CH2)1-4OH; and
n is 1, 2, 3, 4 or 5.

### Claim 90 (depends on 89)

The compound of claim 89, wherein n is 4.

### Claim 91 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90)

A method for the treatment of an inflammatory disorder, comprising administering to a host in need thereof an effective treatment amount of the compound of any one of claims 67-90.

### Claim 92 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90)

A method for the treatment of a cardiovascular disorder, comprising administering to a host in need thereof an effective treatment amount of the compound of any one of claims 67-90.

### Claim 93 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90)

A method for treatment of a disorder mediated by VCAM-1, comprising administering to a host in need thereof an effective treatment amount of the compound of any one of claims 67-90.

### Claim 94 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90)

A method of treating an immune response, comprising administering to a host in need thereof an effective treatment amount of the compound of any one of claims 67-90.
